Article ; Online: Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine.
2022 Volume 145, Issue 6, Page(s) 669–675
Abstract: Background: To evaluate treatment satisfaction with galcanezumab as a patient-reported outcome measure (PROM) in migraine.: Methods: Patients with ≥8 headache days/month that had failed at ≥3 medications were included. Demographic and medical history ...
| Abstract | Background: To evaluate treatment satisfaction with galcanezumab as a patient-reported outcome measure (PROM) in migraine. Methods: Patients with ≥8 headache days/month that had failed at ≥3 medications were included. Demographic and medical history were collected. Patient´s satisfaction (effectiveness, safety, convenience, and global satisfaction [GS]) was assessed by the Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM-1.4©). Results: We included 30 patients with migraine (76.7% chronic migraine). After 12 weeks of galcanezumab treatment, median monthly headache days (MHDs) decreased 11.5 (IQR 14.0) and median monthly migraine days (MMDs) 9.0 (IQR 7.5); at 24 weeks, the change was 15.0 (IQR 12.0) and 8.0 days (IQR 6.0). HIT-6 score decreased from 68.0 (IQR 7.5) to 54.0 (IQR 9.5) at 12 weeks (p < .001) and to 52.0 (IQR12.0) at 24 weeks (p < .001) and MIDAS from 60.0 (IQR 62.7) to 25.5 (IQR 41.2, p = .004) and 7.0 (IQR 18.5, p < .001), respectively. TSQM-1.4© at 12 weeks was higher compared to other preventive therapy in effectiveness (80.6/50.4, p < .001), convenience (83.3/66.7, p = .001), and GS (78.6/50.0, p < .001). These rates of satisfaction were similar at 24 weeks of galcanezumab treatment. Reductions in HIT-6 (r = -.444, p = .014), MIDAS (r = -.423, p = .020), MMDs (r = -.515, p = .004), and MHDs (r = -.477, p = .008) were associated significantly with GS at 12 weeks. This correlation was significantly associated with changes in HIT-6 and MHDs at 24 weeks. Conclusions: The results of this study suggest that migraine patients receiving galcanezumab are significantly more satisfied compared to other preventive therapies, associating treatment GS with meaningful reductions in frequency, impact, and disability caused by migraine. |
|---|---|
| MeSH term(s) | Antibodies, Monoclonal/therapeutic use ; Calcitonin Gene-Related Peptide ; Headache ; Humans ; Migraine Disorders/drug therapy ; Patient Reported Outcome Measures ; Patient Satisfaction ; Personal Satisfaction |
| Chemical Substances | Antibodies, Monoclonal ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z) |
| Language | English |
| Publishing date | 2022-03-03 |
| Publishing country | Denmark |
| Document type | Journal Article |
| ZDB-ID | 90-5 |
| ISSN | 1600-0404 ; 0001-6314 |
| ISSN (online) | 1600-0404 |
| ISSN | 0001-6314 |
| DOI | 10.1111/ane.13599 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ui I Zs.142: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.